Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The PIM kinase family plays a role in tumorigenesis.
• PIM2's function in primary T cells and anti-tumor immunity is understudied.
• PIM2 is distinct from other isoforms and inhibits T-cell responses.

Purpose of the Study:

• To investigate the role of PIM2 as a regulator of anti-tumor immunity.
• To elucidate the mechanisms by which PIM2 affects T cell function.
• To evaluate PIM2 inhibition as a therapeutic strategy in cancer immunotherapy.

Main Methods:

• Utilized murine cancer models (breast cancer, melanoma, leukemia) with Pim2-deficient T cells.
• Analyzed cytokine production, metabolic activity, TCF1 expression, and memory phenotype in CD8 T cells.
• Investigated PIM2's role in autophagy, glycolysis, and EZH2 activity.
• Tested PIM2 inhibitor JP11646 in murine models and engineered human T cells (TCR-T, CAR-T).

Main Results:

• Pim2 deficiency enhanced T cell-mediated tumor control and effector functions.
• Pim2 deficiency promoted a memory-like phenotype in CD8 T cells.
• PIM2 impairs T cell anti-tumor immunity by inhibiting autophagy and glycolysis.
• PIM2 inhibition of EZH2 activity disrupts CD8 T cell memory.
• PIM2 inhibition with JP11646 enhanced anti-tumor T cell responses in mice and humans.

Conclusions:

• PIM2 is a key negative regulator of anti-tumor immunity.
• Targeting PIM2 enhances effector differentiation and persistence of CD8 T cells.
• PIM2 inhibition is a promising strategy for improving cancer immunotherapy.